Recent ALT News
- Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) • GlobeNewswire Inc. • 07/09/2025 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/26/2025 11:30:26 AM
- Altimmune Shares Slide 37% Despite Hitting Key MASH Trial Goals • IH Market News • 06/26/2025 11:18:23 AM
- Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH • GlobeNewswire Inc. • 06/26/2025 11:00:00 AM
- Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 • GlobeNewswire Inc. • 06/25/2025 11:12:07 PM
- Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions • GlobeNewswire Inc. • 06/13/2025 11:30:00 AM
- Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) • GlobeNewswire Inc. • 05/19/2025 11:30:00 AM
- Altimmune to Participate at Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/14/2025 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2025 08:55:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2025 11:04:35 AM
- Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital • GlobeNewswire Inc. • 05/13/2025 11:00:00 AM
- Altimmune Announces First Quarter 2025 Financial Results and Business Update • GlobeNewswire Inc. • 05/13/2025 11:00:00 AM
- Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™ • GlobeNewswire Inc. • 05/08/2025 11:30:00 AM
- Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 • GlobeNewswire Inc. • 05/06/2025 11:30:00 AM
- Altimmune to Present at Upcoming EASL International Liver Congress™ 2025 • GlobeNewswire Inc. • 05/01/2025 11:30:00 AM
- Altimmune to Participate in the Citizens Life Sciences Conference • GlobeNewswire Inc. • 04/30/2025 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2025 08:15:22 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/14/2025 04:15:11 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2025 08:03:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2025 08:05:11 PM
- Altimmune to Host Virtual R&D Day on March 13, 2025 • GlobeNewswire Inc. • 03/06/2025 12:30:00 PM
- Altimmune to Participate in the Leerink Global Healthcare Conference • GlobeNewswire Inc. • 03/03/2025 12:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/27/2025 09:49:48 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2025 09:36:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2025 12:05:35 PM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM